At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INN Summit Hotel Properties
Market Closed 03-20 16:00:00 EDT
4.17
-0.21
-4.79%
盘后4.17
+0.000.00%
18:03 EDT
High4.40Low4.16Vol19.72M
Open4.40D1 Closing4.38Amplitude5.59%
Mkt Cap453.71MTradable Cap453.71MTotal Shares108.80M
T/O82.44MT/O Rate18.13%Tradable Shares108.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Dow Jones  ·  03-19 20:00
Press Release: Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Analysts Offer Insights on Real Estate Companies: Summit Hotel Properties (INN) and Pebblebrook Hotel (PEB)
TIPRANKS  ·  03-04
Analysts Offer Insights on Real Estate Companies: Summit Hotel Properties (INN) and Pebblebrook Hotel (PEB)
Summit Hotel Properties Eyes Gradual Rebound After Tough Year
TIPRANKS  ·  03-03
Summit Hotel Properties Eyes Gradual Rebound After Tough Year
Summit Hotel Properties Inc. Publishes Investor Presentation on Portfolio Performance, Capital Allocation and Balance Sheet Strategy
Reuters  ·  03-03
Summit Hotel Properties Inc. Publishes Investor Presentation on Portfolio Performance, Capital Allocation and Balance Sheet Strategy
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
GlobeNewswire  ·  02-26
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
BRIEF-Summit Hotel Properties Inc Files For Mixed Shelf Of Up To $500 Million
Reuters  ·  02-26
BRIEF-Summit Hotel Properties Inc Files For Mixed Shelf Of Up To $500 Million
Summit Hotel Properties Declares $0.08 Quarterly Dividend
Reuters  ·  02-26
Summit Hotel Properties Declares $0.08 Quarterly Dividend
Summit Hotel Properties (INN) posts FY 2025 net loss of USD 23.6 million from net income of USD 25.1 million
Reuters  ·  02-26
Summit Hotel Properties (INN) posts FY 2025 net loss of USD 23.6 million from net income of USD 25.1 million
BRIEF-Summit Hotel Properties Q4 Adjusted FFO Per Share USD 0.18
Reuters  ·  02-26
BRIEF-Summit Hotel Properties Q4 Adjusted FFO Per Share USD 0.18
Summit Hotel Properties 2026 Outlook Pro Forma Revpar Growth 0.00 % to 3.00 %
THOMSON REUTERS  ·  02-26
Summit Hotel Properties 2026 Outlook Pro Forma Revpar Growth 0.00 % to 3.00 %
Summit Hotel Properties Inc - Has No Debt Maturities Until 2028
THOMSON REUTERS  ·  02-26
Summit Hotel Properties Inc - Has No Debt Maturities Until 2028
Summit Hotel Properties Q4 Ffo per Share USD 0.16
THOMSON REUTERS  ·  02-26
Summit Hotel Properties Q4 Ffo per Share USD 0.16
Summit Hotel Properties Inc Outlook Fye 2026 Adj Ffo per Share $0.73 - $0.85
THOMSON REUTERS  ·  02-26
Summit Hotel Properties Inc Outlook Fye 2026 Adj Ffo per Share $0.73 - $0.85
Summit Hotel Properties Inc expected to post a loss of 6 cents a share - Earnings Preview
Reuters  ·  02-24
Summit Hotel Properties Inc expected to post a loss of 6 cents a share - Earnings Preview
Summit Hotel Properties Declares Q4 2025 Dividends
Reuters  ·  01-23
Summit Hotel Properties Declares Q4 2025 Dividends
Press Release: SUMMIT HOTEL PROPERTIES DECLARES FOURTH QUARTER 2025 DIVIDENDS
Dow Jones  ·  01-23
Press Release: SUMMIT HOTEL PROPERTIES DECLARES FOURTH QUARTER 2025 DIVIDENDS
Summit Hotel Properties Inc. to Release Fourth Quarter and Full Year 2025 Results
Reuters  ·  01-13
Summit Hotel Properties Inc. to Release Fourth Quarter and Full Year 2025 Results
Director Mehulkumar Bhikhubhai Patel Reports Disposal of Summit Hotel Properties Inc. Common Shares
Reuters  ·  01-07
Director Mehulkumar Bhikhubhai Patel Reports Disposal of Summit Hotel Properties Inc. Common Shares
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
GlobeNewswire  ·  01-06
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
Director Mehulkumar Bhikhubhai Patel Reports Disposal of Summit Hotel Properties Inc. Common Shares
Reuters  ·  2025-12-23
Director Mehulkumar Bhikhubhai Patel Reports Disposal of Summit Hotel Properties Inc. Common Shares

Introduction

Company Name.
Summit Hotel Properties
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Summit Hotel Properties, Inc. is a publicly traded real estate investment trust focused on owning premium-branded lodging properties with efficient operating models primarily in the upscale segment of the lodging industry. As of November 1, 2023, the Company's portfolio consisted of 101 assets, 57 of which are wholly owned, with a total of 15,035 guestrooms located in 24 states.
Issue price:
--